Brian A. Lanman

Amgen · company speakers →

provided insights into AMG 410, a small molecule inhibitor of the KRAS signaling pathway that is often mutated in a variety of cancer types and represents a promising target, especially in pancreatic cancer.

Is this you? Claim this profile →

No public contact links on file.

Speaking history

AACR Drug Discovery and Development (AACR D3)

21 July 2026 Boston, United States “AMG 410: Pan-KRAS Inhibitor in Pancreatic Cancer”

Sourcing speakers for your event?

Browse the speaker directory →